Cargando…

TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer

Background: TRIM37 (Tripartite Motif Containing 37) is an E3 ubiquitin ligase for histone H2A and inhibits transcription in several genes. However, it is not known whether it plays a role in gastric cancer (GC). In this study, we tested whether TRIM37 acts as a cancer-promoting factor by being overe...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishibeppu, Keiji, Komatsu, Shuhei, Kiuchi, Jun, Kishimoto, Takuma, Takashima, Yusuke, Shoda, Katsutoshi, Arita, Tomohiro, Kosuga, Toshiyuki, Konishi, Hirotaka, Shiozaki, Atsushi, Kubota, Takeshi, Okamoto, Kazuma, Fujiwara, Hitoshi, Tsuda, Hitoshi, Otsuji, Eigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739001/
https://www.ncbi.nlm.nih.gov/pubmed/33391428
http://dx.doi.org/10.7150/jca.47577
_version_ 1783623240681259008
author Nishibeppu, Keiji
Komatsu, Shuhei
Kiuchi, Jun
Kishimoto, Takuma
Takashima, Yusuke
Shoda, Katsutoshi
Arita, Tomohiro
Kosuga, Toshiyuki
Konishi, Hirotaka
Shiozaki, Atsushi
Kubota, Takeshi
Okamoto, Kazuma
Fujiwara, Hitoshi
Tsuda, Hitoshi
Otsuji, Eigo
author_facet Nishibeppu, Keiji
Komatsu, Shuhei
Kiuchi, Jun
Kishimoto, Takuma
Takashima, Yusuke
Shoda, Katsutoshi
Arita, Tomohiro
Kosuga, Toshiyuki
Konishi, Hirotaka
Shiozaki, Atsushi
Kubota, Takeshi
Okamoto, Kazuma
Fujiwara, Hitoshi
Tsuda, Hitoshi
Otsuji, Eigo
author_sort Nishibeppu, Keiji
collection PubMed
description Background: TRIM37 (Tripartite Motif Containing 37) is an E3 ubiquitin ligase for histone H2A and inhibits transcription in several genes. However, it is not known whether it plays a role in gastric cancer (GC). In this study, we tested whether TRIM37 acts as a cancer-promoting factor by being overexpressed in GC. Methods: We analyzed GC cell lines and 124 primary tumors, which were curatively resected in our hospital between 2001 and 2003. Results: Overexpression of the TRIM37 protein was detected in almost all GC cell lines and GC samples (76 out of 124 cases) and was significantly correlated with lymphatic and venous invasion, advanced T-Stage, N-Stage, histology and high recurrence rate. Patients with TRIM37 overexpressing tumors had a worse survival rate than those with non-expressing tumors (P=0.0057). Moreover, TRIM37 positivity was identified as an independent factor predicting worse outcomes (P=0.018, Hazard ratio 3.41). The apoptotic cell analysis showed that the knockdown of TRIM37 increased apoptosis in comparison with the control. In TRIM37 overexpressing GC cells, knockdown of TRIM37 suppressed the migration and invasion. Conclusions: TRIM37 plays a crucial role in tumor malignant potential through its overexpression and highlight its usefulness as a prognostic factor and potential therapeutic target in GC.
format Online
Article
Text
id pubmed-7739001
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-77390012021-01-01 TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer Nishibeppu, Keiji Komatsu, Shuhei Kiuchi, Jun Kishimoto, Takuma Takashima, Yusuke Shoda, Katsutoshi Arita, Tomohiro Kosuga, Toshiyuki Konishi, Hirotaka Shiozaki, Atsushi Kubota, Takeshi Okamoto, Kazuma Fujiwara, Hitoshi Tsuda, Hitoshi Otsuji, Eigo J Cancer Research Paper Background: TRIM37 (Tripartite Motif Containing 37) is an E3 ubiquitin ligase for histone H2A and inhibits transcription in several genes. However, it is not known whether it plays a role in gastric cancer (GC). In this study, we tested whether TRIM37 acts as a cancer-promoting factor by being overexpressed in GC. Methods: We analyzed GC cell lines and 124 primary tumors, which were curatively resected in our hospital between 2001 and 2003. Results: Overexpression of the TRIM37 protein was detected in almost all GC cell lines and GC samples (76 out of 124 cases) and was significantly correlated with lymphatic and venous invasion, advanced T-Stage, N-Stage, histology and high recurrence rate. Patients with TRIM37 overexpressing tumors had a worse survival rate than those with non-expressing tumors (P=0.0057). Moreover, TRIM37 positivity was identified as an independent factor predicting worse outcomes (P=0.018, Hazard ratio 3.41). The apoptotic cell analysis showed that the knockdown of TRIM37 increased apoptosis in comparison with the control. In TRIM37 overexpressing GC cells, knockdown of TRIM37 suppressed the migration and invasion. Conclusions: TRIM37 plays a crucial role in tumor malignant potential through its overexpression and highlight its usefulness as a prognostic factor and potential therapeutic target in GC. Ivyspring International Publisher 2021-01-01 /pmc/articles/PMC7739001/ /pubmed/33391428 http://dx.doi.org/10.7150/jca.47577 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Nishibeppu, Keiji
Komatsu, Shuhei
Kiuchi, Jun
Kishimoto, Takuma
Takashima, Yusuke
Shoda, Katsutoshi
Arita, Tomohiro
Kosuga, Toshiyuki
Konishi, Hirotaka
Shiozaki, Atsushi
Kubota, Takeshi
Okamoto, Kazuma
Fujiwara, Hitoshi
Tsuda, Hitoshi
Otsuji, Eigo
TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer
title TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer
title_full TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer
title_fullStr TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer
title_full_unstemmed TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer
title_short TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer
title_sort trim37 contributes to malignant outcomes and cddp resistance in gastric cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739001/
https://www.ncbi.nlm.nih.gov/pubmed/33391428
http://dx.doi.org/10.7150/jca.47577
work_keys_str_mv AT nishibeppukeiji trim37contributestomalignantoutcomesandcddpresistanceingastriccancer
AT komatsushuhei trim37contributestomalignantoutcomesandcddpresistanceingastriccancer
AT kiuchijun trim37contributestomalignantoutcomesandcddpresistanceingastriccancer
AT kishimototakuma trim37contributestomalignantoutcomesandcddpresistanceingastriccancer
AT takashimayusuke trim37contributestomalignantoutcomesandcddpresistanceingastriccancer
AT shodakatsutoshi trim37contributestomalignantoutcomesandcddpresistanceingastriccancer
AT aritatomohiro trim37contributestomalignantoutcomesandcddpresistanceingastriccancer
AT kosugatoshiyuki trim37contributestomalignantoutcomesandcddpresistanceingastriccancer
AT konishihirotaka trim37contributestomalignantoutcomesandcddpresistanceingastriccancer
AT shiozakiatsushi trim37contributestomalignantoutcomesandcddpresistanceingastriccancer
AT kubotatakeshi trim37contributestomalignantoutcomesandcddpresistanceingastriccancer
AT okamotokazuma trim37contributestomalignantoutcomesandcddpresistanceingastriccancer
AT fujiwarahitoshi trim37contributestomalignantoutcomesandcddpresistanceingastriccancer
AT tsudahitoshi trim37contributestomalignantoutcomesandcddpresistanceingastriccancer
AT otsujieigo trim37contributestomalignantoutcomesandcddpresistanceingastriccancer